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and has been, the major stumbling block of any pediatric medication initiative such as the development of the
KIDs List. This is complicated by the fact that 50% of the
drugs that are used in pediatrics in the United States
are utilized in an ‘off-label’ fashion. Given the paucity
of solid evidence for most drugs, the authors clearly
explain their rationale for the various categories that
they have chosen. They stress that this is a guidance
document, “meant to serve as a clinical tool and is not
meant to replace clinical judgment or to be used in a
punitive manner.”1
Another limitation is that this list is limited to drugs
available on the US market. Issues may arise with the
inclusion on the KIDs List of some drugs that are on
the World Health Organization’s Model List of Essential
Medicines in Children.4 This could be problematic for
areas of the world in which some of the therapeutic
alternatives used in the United States may not be
available.
It will be interesting to see if the KIDs List results in
any potential legal and regulatory issues (including
reimbursement) in the United States or elsewhere.
The potential impact on the utilization of the drugs on
this list is an area that should be closely followed. The
list may affect formulary lists for hospitals and other
organizations. A KIDs List application that works in
conjunction with other types of clinical monitoring (e.g.,
drug interactions, pharmacogenomics, clinical features)
would be an interesting future direction.
We salute the Pediatric Pharmacy Association for
supporting, and the authors for putting together, this
inaugural version of the KIDs List. The KIDs List is a
call for organizations such as the Pediatric Pharmacy
Association and the American Academy of Pediatrics
to take leadership roles in moving the needed research
forward and in developing collaborative working relationships with colleagues in the rest of the world.
The KIDs List is not perfect, a fact acknowledged
by the authors. However, it is a very important document in that it takes the first steps in a new direction
to enhance drug safety for children and to provide
guidance to clinicians and direction and inspiration to
our next generation of pediatric pharmacy and drug
therapy researchers.
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In this issue of the Journal Meyers et al1 have published the KIDs List, the first-ever list of drugs that are
potentially inappropriate for use in pediatrics. The
authors are to be congratulated for their considerable
effort in acquiring, reviewing, and finally incorporating
the evidence to produce this list. For far too long such
a document has been merely a concept in the minds
of many pediatric practitioners. The concept has now
become reality.
Despite the many large and active children’s hospitals across North America, the reality of child health
care is that most children are cared for in settings in
which adult and pediatric care are mixed. Many of the
medications dispensed to children are prescribed by
non-pediatricians and in settings where information
resources for pediatric drug information may be quite
limited.2 While efficacy is commonly considered in
therapeutic decision making, in many cases safety is
not considered to the same extent. This is especially
germane when drugs that are commonly used in adults
may cause problems in children, notably in infants. The
portrayal of the child as a “Therapeutic Orphan,” coined
by Shirkey over 50 years ago, remains despite many
efforts to relegate it to history.3 It can only be hoped
that the availability of the KIDs List will help to erase
that picture.
How can the KIDs List begin to do this? The first and
most obvious way is to serve as a guidance document,
both for prescribers as well as for pharmacists, who
monitor patients and provide therapeutic advice for
clinicians. Another way in which the list will be useful is
that its publication helps us to identify specific areas in
which research and further study are needed, not only
with regard to medications per se but also more broadly.
This list is prepared for drugs that are available in the
United States specifically. Certainly, it will be useful in
other areas of the world, but medications that are used
in children only in other areas of the world also need
to undergo similar scrutiny. Ideally this list will stimulate
professional associations, research funders, and federal
regulators to support clinical research that will provide
more information to help guide practitioners.
There are limitations to the KIDs List, which are clearly
addressed by the authors. A lack of robust evidence is,
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